189 related articles for article (PubMed ID: 31195990)
1. The association of hepatitis c virus infection status with serum glucose levels.
Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
[TBL] [Abstract][Full Text] [Related]
2. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus.
Qing S; Ji D; Li B; Li F; Wang Y; Niu X; Ling B; Meng Y; Lau G; Chen G
Ann Saudi Med; 2015; 35(4):293-7. PubMed ID: 26497709
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
[TBL] [Abstract][Full Text] [Related]
4. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
[TBL] [Abstract][Full Text] [Related]
5. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
6. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
[TBL] [Abstract][Full Text] [Related]
7. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
Grasso A; Malfatti F; De Leo P; Martines H; Fabris P; Toscanini F; Anselmo M; Menardo G
J Hepatol; 2009 Dec; 51(6):984-90. PubMed ID: 19695729
[TBL] [Abstract][Full Text] [Related]
9. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
[TBL] [Abstract][Full Text] [Related]
12. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
14. Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
Fattovich G; Baroni GS; Pasino M; Pierantonelli I; Covolo L; Ieluzzi D; Passigato N; Tonon A; Faraci MG; Guido M; Negro F
Dig Liver Dis; 2012 May; 44(5):419-25. PubMed ID: 22277808
[TBL] [Abstract][Full Text] [Related]
15. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Özdoğan O; Yaraş S; Ateş F; Üçbilek E; Sezgin O; Altıntaş E
Turk J Gastroenterol; 2020 May; 31(5):384-392. PubMed ID: 32519958
[TBL] [Abstract][Full Text] [Related]
16. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
17. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
18. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
Khattab MA; Eslam M; Shatat M; Abd-Aalhalim H; Mousa YI; Samir F; Aly H; Shaker O; Shaker Y
J Gastrointestin Liver Dis; 2012 Mar; 21(1):59-65. PubMed ID: 22457861
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]